1.26
price down icon0.79%   -0.01
after-market After Hours: 1.29 0.03 +2.38%
loading

Pds Biotechnology Corporation Stock (PDSB) Latest News

pulisher
07:03 AM

Where Do Analysts Think The PDS Biotechnology Corporation (NASDAQ: PDSB) Is Going - Stocks Register

07:03 AM
pulisher
02:50 AM

PDS Biotechnology (NASDAQ:PDSB) Given Buy Rating at HC Wainwright - Defense World

02:50 AM
pulisher
Feb 24, 2025

Do you want to know where to find good stock? Take a look at PDS Biotechnology Corporation’s (NASDAQ:PDSB) Sentiment Analysis – US Post News - US Post News

Feb 24, 2025
pulisher
Feb 24, 2025

PDS Biotech stock plunges to 52-week low of $1.25 - Investing.com

Feb 24, 2025
pulisher
Feb 24, 2025

PDS Biotech Announces Circulating Tumor DNA Results for Versamune® HPV in IMMUNOCERV Trial Published in Clinical Cancer Research - The Manila Times

Feb 24, 2025
pulisher
Feb 24, 2025

PDS Biotechnology Reports Promising Phase 2 Results for Versamune® HPV in Treating HPV16-Positive Cancers; Phase 3 Trial Planned for Q1 2025 - Nasdaq

Feb 24, 2025
pulisher
Feb 24, 2025

Cancer Breakthrough? PDS Biotech's HPV Treatment Shows Perfect Survival Rate in Latest Trial - StockTitan

Feb 24, 2025
pulisher
Feb 20, 2025

PDS Biotech to Participate at B. Riley Securities Precision Oncology & Radiopharma Conference 2025 - The Manila Times

Feb 20, 2025
pulisher
Feb 20, 2025

Can PDS Biotech's Latest Oncology Developments Transform Cancer Treatment? CEO to Reveal Strategy - StockTitan

Feb 20, 2025
pulisher
Feb 20, 2025

PDSB stock touches 52-week low at $1.3 amid market challenges - MSN

Feb 20, 2025
pulisher
Feb 17, 2025

Cancer Vaccines Market on Track for Major Expansion in the - GlobeNewswire

Feb 17, 2025
pulisher
Feb 17, 2025

Cancer Vaccines Market on Track for Major Expansion in - One News Page

Feb 17, 2025
pulisher
Feb 12, 2025

PDSB stock touches 52-week low at $1.3 amid market challenges By Investing.com - Investing.com South Africa

Feb 12, 2025
pulisher
Feb 12, 2025

PDS Biotechnology (NASDAQ:PDSB) Trading Down 5.8%What's Next? - MarketBeat

Feb 12, 2025
pulisher
Feb 10, 2025

PDS Biotech set for Phase 3 trial in HPV-positive cancer treatment - MSN

Feb 10, 2025
pulisher
Feb 08, 2025

FDA approves PDS Biotech's Phase 3 trial design for cancer therapy - MSN

Feb 08, 2025
pulisher
Feb 08, 2025

PDS Biotechnology (NASDAQ:PDSB) Shares Down 5.8% – What’s Next? - Defense World

Feb 08, 2025
pulisher
Feb 06, 2025

Clinical Trials News Live Feed - StockTitan

Feb 06, 2025
pulisher
Feb 05, 2025

PDS Biotech reaffirms guidance for clinical trial - ShareCast

Feb 05, 2025
pulisher
Feb 05, 2025

PDS Biotech Reaffirms Guidance for First Quarter Initiation of VERSATILE-003 Phase 3 Clinical Trial in HPV16-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma - Marketscreener.com

Feb 05, 2025
pulisher
Feb 05, 2025

PDS Biotech Advances Novel HPV Cancer Treatment to Phase 3 Trial with FDA Fast Track Status | PDSB Stock News - StockTitan

Feb 05, 2025
pulisher
Jan 22, 2025

Tuberculosis Clinical Trial Pipeline Appears Robust With 30+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - Yahoo Finance

Jan 22, 2025
pulisher
Jan 20, 2025

PDS Biotechnology Corporation (NASDAQ: PDSB): Hidden Gems In A Time Of Volatility - Stocks Register

Jan 20, 2025
pulisher
Jan 20, 2025

Contrasting PDS Biotechnology (NASDAQ:PDSB) & Lipella Pharmaceuticals (NASDAQ:LIPO) - Defense World

Jan 20, 2025
pulisher
Jan 20, 2025

Head-To-Head Contrast: Bicara Therapeutics (NASDAQ:BCAX) & Lipella Pharmaceuticals (NASDAQ:LIPO) - Defense World

Jan 20, 2025
pulisher
Jan 17, 2025

Inspirion Wealth Advisors LLC Sells 270,862 Shares of PDS Biotechnology Co. (NASDAQ:PDSB) - MarketBeat

Jan 17, 2025
pulisher
Jan 11, 2025

PDSB stock touches 52-week low at $1.51 amid market challenges - Investing.com Nigeria

Jan 11, 2025
pulisher
Jan 10, 2025

Spero Therapeutics names Esther Rajavelu as Interim President and CEO (NASDAQ:SPRO) - Seeking Alpha

Jan 10, 2025
pulisher
Jan 09, 2025

Geode Capital Management LLC Acquires 37,142 Shares of PDS Biotechnology Co. (NASDAQ:PDSB) - Defense World

Jan 09, 2025
pulisher
Jan 09, 2025

Ball Co. (NYSE:BALL) Shares Sold by GAMMA Investing LLC - Defense World

Jan 09, 2025
pulisher
Jan 08, 2025

PDS Planning Inc Has $23.21 Million Stock Position in Apple Inc. (NASDAQ:AAPL) - Defense World

Jan 08, 2025
pulisher
Jan 07, 2025

Immuneering stock jumps on lead asset data (IMRX:NASDAQ) - Seeking Alpha

Jan 07, 2025
pulisher
Jan 05, 2025

Meet Gauzy and Research Frontiers at CES This Week to See the Latest in SPD-SmartGlass Products and Technology - Quantisnow

Jan 05, 2025
pulisher
Jan 04, 2025

State Street Corp Sells 18,700 Shares of PDS Biotechnology Co. (NASDAQ:PDSB) - Defense World

Jan 04, 2025
pulisher
Dec 23, 2024

PDS Biotechnology Corp Announces Pricing Of Public Offering Of About $12 mln Shares - Reuters

Dec 23, 2024
pulisher
Dec 18, 2024

PDS Biotechnology (NASDAQ:PDSB) Receives "Buy" Rating from HC Wainwright - MarketBeat

Dec 18, 2024
pulisher
Dec 11, 2024

DBV stock rallies post-market on FDA Viaskin update (NASDAQ:DBVT) - Seeking Alpha

Dec 11, 2024
pulisher
Dec 06, 2024

PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Dec 06, 2024
pulisher
Dec 06, 2024

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Dec 06, 2024
pulisher
Dec 06, 2024

PDS Biotech Grants Stock Options to New Clinical Employee Under Inducement Plan - StockTitan

Dec 06, 2024
pulisher
Dec 03, 2024

PDSBPDS Biotechnology Corporation Latest Stock News & Market Updates - StockTitan

Dec 03, 2024
pulisher
Dec 03, 2024

PDS Biotech to Host Key Opinion Leader Event on December 17 at 12 p.m. ET - The Manila Times

Dec 03, 2024
pulisher
Dec 03, 2024

PDS Biotech Announces Expert Panel on HPV16 Cancer Treatment Phase 3 Trial - StockTitan

Dec 03, 2024
pulisher
Dec 03, 2024

A share offer that's hard to refuse - Investors Chronicle

Dec 03, 2024
pulisher
Dec 02, 2024

BioGene Therapeutics Welcomes Stephen Glover to Its Board of Directors - Newsfile

Dec 02, 2024
pulisher
Dec 02, 2024

PreveCeutical Medical Appoints Biopharma Veteran Stephen Glover to BioGene Board - StockTitan

Dec 02, 2024
$74.40
price up icon 0.53%
$22.96
price up icon 2.04%
$33.69
price down icon 0.33%
$357.50
price down icon 0.20%
$110.97
price down icon 5.14%
biotechnology ONC
$259.70
price up icon 0.47%
Cap:     |  Volume (24h):